Xenova
Executive Summary
British drug discovery firm receives second $4.2 mil. equity investment from Genentech, marking "completion of a key milestone" in the collaboration between the two firms. The agreement combines Xenova's ability to screen 23,000 microorganisms for small molecule drug leads with Genentech's technology for discovering disease- specific molecular targets. The targets include hypertension, congestive heart disease, atherosclerosis, inflammation and autoimmune disease ("The Pink Sheet" Oct. 14, 1991, T&G-3).
|
British drug discovery firm receives second $4.2 mil. equity
investment from Genentech, marking "completion of a key milestone"
in the collaboration between the two firms. The agreement combines
Xenova's ability to screen 23,000 microorganisms for small molecule
drug leads with Genentech's technology for discovering disease-
specific molecular targets. The targets include hypertension,
congestive heart disease, atherosclerosis, inflammation and
autoimmune disease ("The Pink Sheet" Oct. 14, 1991, T&G-3). |